Webinar replay

Biopharma Dealmaking in 2023. Perspective and Projections​

Download the Partner'23 eBook now

Deal flow decreased, average deal values dropped, and headline grabbing M&As slowed to a trickle. Inflation soared, IPOs cratered, and SPAC just might be the new four-letter-word. After a year where the global economy slowed and uncertainty reigned, what does 2023 hold for the biopharma industry?​

Chris Dokomajilar, Founder and CEO at Dealforma, returns to Inova to offer his third annual review of the year in life science partnering. He’ll unlock all the trends in the dealmaking data and draw on his deep industry expertise to project what we’re likely to see in the biopharma dealmaking in 2023.​

Watch the replay to learn:​

  • Why large pharma merger activity slowed​
  • Where VC investments flowed, and why
  • How and where pre-clinical biotechs raised capital​
  • Whether licensing upfronts will bounce back in the new year​
Watch this replay to get expert insights from our panelist:
Chris Dokomajilar
Chris Dokomajilar
Founder and CEO
DealForma

Please complete the form below

All fields marked with a * are required.
By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.
Partner23-Slide3
Partner23-Slide7
Partner23-Slide9
Preview eBook

Partner’23: Data, Deals, and Directions

  • IPO Activity at 10 Year Lows. Number and value of IPOs bottom out.
  • Paying for Quality. 

    Median Upfront Cash & Equity by Stage at Signing with Large Cap Biopharma 2018-2022 ($M).

  • Top 5 Dealmakers. By Deal Count 2022.
Download the Partner'23 eBook now

Resources you may be interested in

samson-ZGjbiukp_-A-unsplash

Partner of Choice. By Choice

Watch webinar replay
AdobeStock_222932981 (1)-min

Biopharma Dealmaking in 2022: Trends & Forecasts

Download whitepaper
Partner23-Slide1

Partner’23: Data, Deals, and Directions

Download whitepaper

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.